DBV Technologies Reports Positive Phase 3 Results for VIASKIN Peanut Patch

DBV Technologies has announced favorable results from its Phase 3 VITESSE trial, evaluating the VIASKIN Peanut patch in children aged 4-7 with peanut allergies. The study met its primary endpoint, with a significant 46.6% response rate in the treatment group compared to 14.8% in the placebo group. This marks a 24.5% difference, surpassing the set threshold of 15%.

The trial involved 654 children, and adverse events were mostly mild to moderate skin reactions. Notably, no serious treatment-related events were reported. The company plans to submit a Biologics License Application (BLA) in the US by mid-2026, potentially leading to the VIASKIN Peanut patch becoming a new option for managing peanut allergy in young children.

DBV will also accelerate its warrant exercise period following these positive results, potentially impacting their upcoming financial strategies.